| symbol |
NTGN |
|---|
| 会社名 | Neon Therapeutics Inc （ネオン・セラピュ―ティクス） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Biotechnology: Biological Products (No Diagnostic Substances)
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets. ネオン・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、がんに対する免疫療法の開発に従事し、がんのネオ抗原標的療法に焦点を当てる。同社は転移性メラノ―マ、非小細胞肺がん、膀胱がんの治療用ニボルマブと組み合わせたネオ抗原ワクチンNEO-PV-01を開発する。固形がん、乳がんの治療ワクチンも手がける。本社所在地はマサチュ―セッツ州ケンブリッジ。 BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
|
|---|
| 本社所在地 | 40 Erie St. Suite 110 Cambridge MA 02139 USA |
|---|
| 代表者氏名 | Cary G. Pfeffer ケーリー・G・フェフェール |
|---|
| 代表者役職名 | Chairman of the Board 取締役会会長 |
|---|
| 電話番号 | +1 617-337-4701 |
|---|
| 設立年月日 | 41548 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2018年 |
|---|
| 従業員数 | 84人 |
|---|
| url | www.neontherapeutics.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/ntgn |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -63.43200 |
|---|
| 終値（lastsale） | 10.06 |
|---|
| 時価総額（marketcap） | 284724900.44 |
|---|
| 時価総額 | 時価総額（百万ドル） 280.76250 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 142.12950 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -75.67200 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Neon Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 74% to $41.8M. Higher net loss reflects Research and development increase of 88% to $25.8M (expense) General and administrative increase of 66% to $7M (expense) Stock-based Compensation in R&D increase from $1.1M to $2.2M (expense). |
|---|
NTGN - ネオン・セラピュ―ティクス （Neon Therapeutics Inc.） ネオン・セラピュ―ティクス